InsidersTradesSigma
Total declarations
Company
▲ Purchases (7 ops.)
▼ Sales (1 ops.)
Insider track record
CFODisclosed buys
7
Disclosed sells
1
T+90 hit rate
0%
T+90 mean return
-19.4%
Across 6 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Kelly John Alexander, Chief Financial Officer. Director active across 1 company, notably Precision Biosciences INC. Aggregated, 25 disclosures have been recorded. Split: 7 buys · 1 sell. Total volume traded: €283k. History available since 31 August 2021. The latest transaction was filed on 17 February 2026 (Levée d'options). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Kelly John Alexander
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations25 total
27,584 shares0Common StockSEC:0001628280-26-009803:0
3,888 sharesCommon StockSEC:0001628280-26-003147:0
3,605 shares0Common StockSEC:0001628280-25-048858:0
14,827 shares@ US$4.2612.0% of flowCommon StockSEC:0001628280-25-034531:0
1,702 sharesCommon StockSEC:0000950170-25-034006:0
44,368 sharesCommon StockSEC:0000950170-25-008012:0
2,113 shares@ US$4.752.5% of flowCommon StockSEC:0000950170-24-141308:0
Canonical exit: 27 Mar 2025 (T+90)
3,000 shares@ US$6.764.9% of flowCommon StockSEC:0000950170-24-129735:0
Canonical exit: 19 Feb 2025 (T+90)
3,605 sharesCommon StockSEC:0000950170-24-121729:0
454 sharesCommon StockSEC:0000950170-24-072050:0
8,334 shares@ US$12.0023.7% of flowCommon StockSEC:0000950170-24-056140:0
506 shares@ US$18.502.2% of flowCommon StockSEC:0000950170-24-053116:0
116,690 sharesCommon StockSEC:0001209191-24-002121:0
108,188 sharesCommon StockSEC:0001209191-23-054546:0
90,000 shares@ US$0.4810.1% of flowCommon StockSEC:0001209191-23-053784:0
Canonical exit: 16 Nov 2023 (T+90)
5,951 shares@ US$0.390.5% of flowCommon StockSEC:0001209191-23-048144:0
90,000 shares@ US$0.4810.1% of flowCommon StockSEC:0001209191-23-046874:0
34,091 sharesCommon StockSEC:0001209191-23-035792:0
20,000 shares@ US$0.864.1% of flowCommon StockSEC:0001209191-23-020154:0
Canonical exit: 15 Jun 2023 (T+90)
11,605 shares@ US$0.952.6% of flowCommon StockSEC:0001209191-23-016835:0
37,037 shares@ US$1.3412.8% of flowCommon StockSEC:0001209191-22-051240:0
Canonical exit: 21 Dec 2022 (T+90)
33,784 shares@ US$1.500.048% mcap46.3% of flowCommon StockSEC:0001209191-22-039100:0
Canonical exit: 20 Sept 2022 (T+90)
34,090 sharesCommon StockSEC:0001209191-22-035405:0
16,677 shares@ US$3.080.047% mcap45.0% of flowCommon StockSEC:0001209191-22-020337:0
Canonical exit: 15 Jun 2022 (T+90)
998 shares@ US$10.680.0090% mcap8.7% of flowCommon StockSEC:0001209191-22-016614:0
25 of 25 declarations
About Kelly John Alexander
Kelly John Alexander is Chief Financial Officer at Precision Biosciences INC (XNAS). He has 25 filings, and across the recent sampled filings from 2022-03-07 to 2026-02-19, buys total EUR 229790 and sells total EUR 53658, with Levée d'options as the most frequent transaction type.
